Unacceptable Principal Diagnosis Codes
ICD-10-CM codes identified as unacceptable when used as principal diagnosis by MCE edit logic.
Source: Definitions of Medicare Code Edits v44.0, edit 9.
Advertisements
Codes on this list
2,666 codes, page 10 of 27.
- T43.596AUnderdosing of other antipsychotics and neuroleptics, initial encounter
- T43.596DUnderdosing of other antipsychotics and neuroleptics, subsequent encounter
- T43.596SUnderdosing of other antipsychotics and neuroleptics, sequela
- T43.605AAdverse effect of unspecified psychostimulants, initial encounter
- T43.605DAdverse effect of unspecified psychostimulants, subsequent encounter
- T43.605SAdverse effect of unspecified psychostimulants, sequela
- T43.606AUnderdosing of unspecified psychostimulants, initial encounter
- T43.606DUnderdosing of unspecified psychostimulants, subsequent encounter
- T43.606SUnderdosing of unspecified psychostimulants, sequela
- T43.615AAdverse effect of caffeine, initial encounter
- T43.615DAdverse effect of caffeine, subsequent encounter
- T43.615SAdverse effect of caffeine, sequela
- T43.616AUnderdosing of caffeine, initial encounter
- T43.616DUnderdosing of caffeine, subsequent encounter
- T43.616SUnderdosing of caffeine, sequela
- T43.625AAdverse effect of amphetamines, initial encounter
- T43.625DAdverse effect of amphetamines, subsequent encounter
- T43.625SAdverse effect of amphetamines, sequela
- T43.626AUnderdosing of amphetamines, initial encounter
- T43.626DUnderdosing of amphetamines, subsequent encounter
- T43.626SUnderdosing of amphetamines, sequela
- T43.635AAdverse effect of methylphenidate, initial encounter
- T43.635DAdverse effect of methylphenidate, subsequent encounter
- T43.635SAdverse effect of methylphenidate, sequela
- T43.636AUnderdosing of methylphenidate, initial encounter
- T43.636DUnderdosing of methylphenidate, subsequent encounter
- T43.636SUnderdosing of methylphenidate, sequela
- T43.655AAdverse effect of methamphetamines, initial encounter
- T43.655DAdverse effect of methamphetamines, subsequent encounter
- T43.655SAdverse effect of methamphetamines, sequela
- T43.656AUnderdosing of methamphetamines, initial encounter
- T43.656DUnderdosing of methamphetamines, subsequent encounter
- T43.656SUnderdosing of methamphetamines, sequela
- T43.695AAdverse effect of other psychostimulants, initial encounter
- T43.695DAdverse effect of other psychostimulants, subsequent encounter
- T43.695SAdverse effect of other psychostimulants, sequela
- T43.696AUnderdosing of other psychostimulants, initial encounter
- T43.696DUnderdosing of other psychostimulants, subsequent encounter
- T43.696SUnderdosing of other psychostimulants, sequela
- T43.8X5AAdverse effect of other psychotropic drugs, initial encounter
- T43.8X5DAdverse effect of other psychotropic drugs, subsequent encounter
- T43.8X5SAdverse effect of other psychotropic drugs, sequela
- T43.8X6AUnderdosing of other psychotropic drugs, initial encounter
- T43.8X6DUnderdosing of other psychotropic drugs, subsequent encounter
- T43.8X6SUnderdosing of other psychotropic drugs, sequela
- T43.95XAAdverse effect of unspecified psychotropic drug, initial encounter
- T43.95XDAdverse effect of unspecified psychotropic drug, subsequent encounter
- T43.95XSAdverse effect of unspecified psychotropic drug, sequela
- T43.96XAUnderdosing of unspecified psychotropic drug, initial encounter
- T43.96XDUnderdosing of unspecified psychotropic drug, subsequent encounter
- T43.96XSUnderdosing of unspecified psychotropic drug, sequela
- T44.0X5AAdverse effect of anticholinesterase agents, initial encounter
- T44.0X5DAdverse effect of anticholinesterase agents, subsequent encounter
- T44.0X5SAdverse effect of anticholinesterase agents, sequela
- T44.0X6AUnderdosing of anticholinesterase agents, initial encounter
- T44.0X6DUnderdosing of anticholinesterase agents, subsequent encounter
- T44.0X6SUnderdosing of anticholinesterase agents, sequela
- T44.1X5AAdverse effect of other parasympathomimetics [cholinergics], initial encounter
- T44.1X5DAdverse effect of other parasympathomimetics [cholinergics], subsequent encounter
- T44.1X5SAdverse effect of other parasympathomimetics [cholinergics], sequela
- T44.1X6AUnderdosing of other parasympathomimetics [cholinergics], initial encounter
- T44.1X6DUnderdosing of other parasympathomimetics [cholinergics], subsequent encounter
- T44.1X6SUnderdosing of other parasympathomimetics [cholinergics], sequela
- T44.2X5AAdverse effect of ganglionic blocking drugs, initial encounter
- T44.2X5DAdverse effect of ganglionic blocking drugs, subsequent encounter
- T44.2X5SAdverse effect of ganglionic blocking drugs, sequela
- T44.2X6AUnderdosing of ganglionic blocking drugs, initial encounter
- T44.2X6DUnderdosing of ganglionic blocking drugs, subsequent encounter
- T44.2X6SUnderdosing of ganglionic blocking drugs, sequela
- T44.3X5AAdverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
- T44.3X5DAdverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter
- T44.3X5SAdverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela
- T44.3X6AUnderdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
- T44.3X6DUnderdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter
- T44.3X6SUnderdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela
- T44.4X5AAdverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter
- T44.4X5DAdverse effect of predominantly alpha-adrenoreceptor agonists, subsequent encounter
- T44.4X5SAdverse effect of predominantly alpha-adrenoreceptor agonists, sequela
- T44.4X6AUnderdosing of predominantly alpha-adrenoreceptor agonists, initial encounter
- T44.4X6DUnderdosing of predominantly alpha-adrenoreceptor agonists, subsequent encounter
- T44.4X6SUnderdosing of predominantly alpha-adrenoreceptor agonists, sequela
- T44.5X5AAdverse effect of predominantly beta-adrenoreceptor agonists, initial encounter
- T44.5X5DAdverse effect of predominantly beta-adrenoreceptor agonists, subsequent encounter
- T44.5X5SAdverse effect of predominantly beta-adrenoreceptor agonists, sequela
- T44.5X6AUnderdosing of predominantly beta-adrenoreceptor agonists, initial encounter
- T44.5X6DUnderdosing of predominantly beta-adrenoreceptor agonists, subsequent encounter
- T44.5X6SUnderdosing of predominantly beta-adrenoreceptor agonists, sequela
- T44.6X5AAdverse effect of alpha-adrenoreceptor antagonists, initial encounter
- T44.6X5DAdverse effect of alpha-adrenoreceptor antagonists, subsequent encounter
- T44.6X5SAdverse effect of alpha-adrenoreceptor antagonists, sequela
- T44.6X6AUnderdosing of alpha-adrenoreceptor antagonists, initial encounter
- T44.6X6DUnderdosing of alpha-adrenoreceptor antagonists, subsequent encounter
- T44.6X6SUnderdosing of alpha-adrenoreceptor antagonists, sequela
- T44.7X5AAdverse effect of beta-adrenoreceptor antagonists, initial encounter
- T44.7X5DAdverse effect of beta-adrenoreceptor antagonists, subsequent encounter
- T44.7X5SAdverse effect of beta-adrenoreceptor antagonists, sequela
- T44.7X6AUnderdosing of beta-adrenoreceptor antagonists, initial encounter
- T44.7X6DUnderdosing of beta-adrenoreceptor antagonists, subsequent encounter
- T44.7X6SUnderdosing of beta-adrenoreceptor antagonists, sequela
- T44.8X5AAdverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter